DIA Exhibit Hall Highlights

EU proposal focuses on a subset of underserved rare diseases—exploring the gaps in those conditions for which there is no approved treatment option.

With lessons from COVID now established, concrete ideas on improving drug development strategy for future health threats are beginning to take shape.

EU’s sweeping push for major pharma reforms to impact the daily practice of clinical trials community.

Dissecting the EMA’s new annual report on milestones reached in clinical research and public health.

Grading the government’s formal response to reform efforts hopeful of boosting UK’s sagging global standing in drug development.

EMA operated-Priority Medicines scheme receives update which will expedite response to applicants.